Skip to main content
COMPLETED RESEARCH: PRACTICE MANAGEMENT
Abstract #PM02

Impact of Drug Repository Program in a Rural Oncology Clinic

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Adverse Events

Presenter: Stephanie Evangelisti, PharmD, MS, BCOP, Oncology Pharmacy Director, Grand Valley Oncology (Community Hospital), CO

Co-Authors: Brenda Butchko, CPhT, Grand Valley Oncology, CO; Alisha Reynolds, Grand Valley Oncology, CO

Background: Rules adopted in 2008, but repealed in 2020, by the Colorado State Legislature and State Board of Pharmacy, allowed patients with cancer or the patient’s family member to donate previously dispensed oral cancer medications to pharmacies for the purpose of redispensing to patients who cannot afford their prescribed medications.1 Because 16% of the population in Mesa County, Colorado, live below the poverty line, Grand Valley Oncology opted to participate in this drug recycling program to increase access and minimize waste of expensive oral cancer medications.

Objective: To determine the impact of the Cancer Drug Repository Program in terms of increased patient access to oral medications used in the treatment of cancer, including side-effect management, and decreased pharmaceutical waste.

Methods: Donations of noncontrolled medications received between January 1, 2019, and December 31, 2019, were reviewed by a pharmacist to ensure that the following conditions were met: used in the treatment of cancer, including side-effect management; stored in the original, unopened, sealed, and tamper-evident packaging; properly stored at room temperature; and within expiration date. If a patient undergoing cancer treatment was uninsured, underinsured, or demonstrated significant financial need, then a financial counselor would meet with the patient to review applicable medication access programs, such as the Cancer Drug Repository Program, manufacturer assistance programs, and grants. The patient, if eligible to participate, was required to acknowledge receipt of donated medication.

Results: A total of 34 medications were donated to the Cancer Drug Repository Program between January 1, 2019, and December 31, 2019. The total average sales price (ASP) for these donated medications was $569,592. Six patients were deemed eligible to participate in the program based on financial need and availability of donated medication; 12 prescriptions (ASP, $240,854) of the available 34 were dispensed to these individuals at the time of repeal.

Conclusion: Financial toxicity can be a significant burden to individuals diagnosed with cancer and their families. Although assistance was limited based on the availability of donated medications, the practice still promoted improved access to oral cancer medications. Resources, such as the drug recycling program, should be utilized to help increase patient access to, and minimize waste of, expensive oral cancer medications. This project was undertaken as a Quality Improvement Initiative at Colorado West Healthcare System (Grand Valley Oncology) and, as such, was not formally supervised by an Institutional Review Board.

  1. Colorado Department of Regulatory Agencies; State Board of Pharmacy. Rule 3.00.80 Return or Exchange of Drugs, Prescriptions, Medical Devices, and Medical Supplies for Dispensing or Donation. HB15-1039, General Assembly of the State of Colorado, 2015.
Related Items
Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study
JHOP - June 2026 Vol 16, No 3 published on February 25, 2026 in Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer
Reconsidering Venetoclax Dosing With Azole Antifungals: The Case for 50 mg
JHOP - April 2026 Vol 16, No 2 published on February 19, 2026 in Review Article, Adverse Events, Dose Escalation/Reduction, Drug–Drug Interaction, Venetoclax
Management Patterns and Perceived Educational Needs Related to Cancer Therapy Cardiovascular Toxicities for Cardio-Oncology Providers
JHOP - June 2026 Vol 16, No 3 published on February 19, 2026 in Original Research, Adverse Events, Drug–Drug Interaction
Risk for Vincristine-Induced Adverse Events With Aprepitant in Pediatric Patients With Rhabdomyosarcoma
JHOP - April 2026 Vol 16, No 2 published on January 20, 2026 in Original Research, Adverse Events, Chemotherapy, Drug–Drug Interaction
Impact of Universal Pegaspargase Premedication on Substitution Rates and Adverse Events
JHOP - August 2026 Vol 16, No 4 published on January 8, 2026 in Original Research, Adverse Events, Pediatric Cancer, Acute Lymphoblastic Leukemia
Evaluation of Initial Weight-Based Tacrolimus Dosing After Allogeneic Hematopoietic Stem Cell Transplant
JHOP - April 2026 Vol 16, No 2 published on January 7, 2026 in Original Research, Adverse Events, Transplant
Implementation of a Cardio-Oncology Pharmacist Position in a Community Cancer Center
JHOP - April 2026 Vol 16, No 2 published on January 2, 2026 in Practical Issues in Pharmacy Management, Adverse Events, Chemotherapy, Drug–Drug Interaction, Oncology Pharmacy Programs/Protocols, Oral Therapy
Analysis of Ifosfamide-Associated Encephalopathy Between 2 Formulations in Adults With Hematologic Cancer
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Adverse Events
Evaluation of Serious Immune-Related Adverse Event Incidence in 200-mg Versus 400-mg Pembrolizumab Regimens
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Adverse Events, Immunotherapy
Evaluation of Bleeding Events in Patients Who Received Ibrutinib With or Without Antithrombotic Therapy
JHOP - February 2026 Vol 16, No 1 published on November 14, 2025 in Original Research, Chemotherapy, Adverse Events